MammaPrint genetic testing reduces chemotherapy overtreatment in breast cancer patients

Share it with your friends Like

Thanks! Share it with your friends!


Martine Piccart, MD, PhD & Head of the Medicine Department at the Jules Bordet Institute and Co-Founder of the Breast International Group (BIG) discusses primary analysis of the EORTC 10041/BIG 3-04 MINDACT study: A prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes at the American Association of Cancer Research Annual Meeting 2016 (AACR16).

MDLinx Conference Coverage – American Association of Cancer Research Annual Meeting 2016:

Smartest Doc & Board Exam Prep:

Follow MDLinx:
Facebook –
Twitter –
Google+ –


Write a comment